Bridgebio Pharma Inc (BBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
Sales | 1,826 | 1,870 | 338 | 73,746 | 1,694 |
Cost of Goods | 651 | 647 | 739 | 700 | 1,348 |
Gross Profit | 1,175 | 1,223 | -401 | 73,046 | 346 |
Operating Expenses | 127,989 | 131,102 | 129,454 | 153,922 | 174,372 |
Operating Income | -126,163 | -129,232 | -129,116 | -80,176 | -173,678 |
Interest Expense | 20,121 | 19,990 | 19,825 | 20,279 | 20,344 |
Other Income | 3,552 | 8,652 | 8,748 | 97,896 | -7,308 |
Pre-tax Income | -142,732 | -140,570 | -140,193 | -2,559 | -201,330 |
Net Income Continuous | -142,732 | -140,570 | -140,193 | -2,559 | -201,330 |
Minority Interests | -2,576 | -2,979 | -2,854 | 7,297 | -4,933 |
Net Income | $-140,156 | $-137,591 | $-137,339 | $-9,856 | $-196,397 |
EPS Basic Total Ops | -0.92 | -0.91 | -0.93 | -0.07 | -1.35 |
EPS Basic Continuous Ops | -0.94 | -0.94 | -0.95 | -0.02 | -1.38 |
EPS Diluted Total Ops | -0.92 | -0.91 | -0.93 | -0.07 | -1.35 |
EPS Diluted Continuous Ops | -0.94 | -0.94 | -0.95 | -0.02 | -1.38 |
EPS Diluted Before Non-Recurring Items | -0.92 | -0.87 | -0.93 | N/A | N/A |
EBITDA(a) | $-124,530 | $-127,572 | $-127,471 | $-78,594 | $-171,794 |